A pivotal Phase 2 study of derazantinib for previously-treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 aberrations: FIDES-01.

Borad MJ, Droz Dit Busset M, Javle MM, Shaib WL, Personeni N, Mody K, Babiker H, Bergamo F, Harris WP, Damjanov N, Macarulla T, Brandi G, Masi G, Abou-Alfa GK, Halfdanarson TR, Knox J, Tam VC, Bernat M, Engelhardt M, Friedmann S, Häckl M, McKernan P, Saulay M, Goff LW, Hollebecque A, Adeva J, Jeffry Evans TR, Bridgewater J, Foerster F, Kendall SD, Roth G, Cunningham D, Vogel A, Niger M, Mahipal A, Mazzaferro V.

Open source

DOI: 10.1097/hep.0000000000001902
Published: 2026-10-27
Container: Hepatology
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1097/hep.0000000000001902,
  title = {A pivotal Phase 2 study of derazantinib for previously-treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 aberrations: FIDES-01.},
  author = {Borad MJ and  Droz Dit Busset M and  Javle MM and  Shaib WL and  Personeni N and  Mody K and  Babiker H and  Bergamo F and  Harris WP and  Damjanov N and  Macarulla T and  Brandi G and  Masi G and  Abou-Alfa GK and  Halfdanarson TR and  Knox J and  Tam VC and  Bernat M and  Engelhardt M and  Friedmann S and  Häckl M and  McKernan P and  Saulay M and  Goff LW and  Hollebecque A and  Adeva J and  Jeffry Evans TR and  Bridgewater J and  Foerster F and  Kendall SD and  Roth G and  Cunningham D and  Vogel A and  Niger M and  Mahipal A and  Mazzaferro V.},
  year = {2026},
  journal = {Hepatology},
  doi = {10.1097/hep.0000000000001902},
  url = {https://doi.org/10.1097/hep.0000000000001902}
}

RIS

TY  - JOUR
TI  - A pivotal Phase 2 study of derazantinib for previously-treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 aberrations: FIDES-01.
AU  - Borad MJ
AU  -  Droz Dit Busset M
AU  -  Javle MM
AU  -  Shaib WL
AU  -  Personeni N
AU  -  Mody K
AU  -  Babiker H
AU  -  Bergamo F
AU  -  Harris WP
AU  -  Damjanov N
AU  -  Macarulla T
AU  -  Brandi G
AU  -  Masi G
AU  -  Abou-Alfa GK
AU  -  Halfdanarson TR
AU  -  Knox J
AU  -  Tam VC
AU  -  Bernat M
AU  -  Engelhardt M
AU  -  Friedmann S
AU  -  Häckl M
AU  -  McKernan P
AU  -  Saulay M
AU  -  Goff LW
AU  -  Hollebecque A
AU  -  Adeva J
AU  -  Jeffry Evans TR
AU  -  Bridgewater J
AU  -  Foerster F
AU  -  Kendall SD
AU  -  Roth G
AU  -  Cunningham D
AU  -  Vogel A
AU  -  Niger M
AU  -  Mahipal A
AU  -  Mazzaferro V.
PY  - 2026
JO  - Hepatology
DO  - 10.1097/hep.0000000000001902
UR  - https://doi.org/10.1097/hep.0000000000001902
ER  -

APA

MJ, B., M, D. D. B., MM, J., WL, S., N, P., K, M., H, B., F, B., WP, H., N, D., T, M., G, B., G, M., GK, A., TR, H., J, K., VC, T., M, B., M, E., S, F., M, H., P, M., M, S., LW, G., A, H., J, A., TR, J. E., J, B., F, F., SD, K., G, R., D, C., A, V., M, N., A, M., & V., M. (2026). A pivotal Phase 2 study of derazantinib for previously-treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 aberrations: FIDES-01.. Hepatology. https://doi.org/10.1097/hep.0000000000001902

Source records

europe-pmc · retrieved 2026-11-10T18:00:10.090Z